

CV Date

29/07/2021

Part A. PERSONAL INFORMATION

First Name *	Jerónimo		
Family Name *	Pachón Díaz		
Sex *		Date of Birth *	
ID number Social Security, Passport *		Phone Number	
URL Web			
Email Address *			
Researcher's identification number	Open Researcher and Contributor ID (ORCID)*	0000-0002-8166-5308	
	Researcher ID	M-4337-2014	
	Scopus Author ID	7005457888	

* Mandatory

A.1. Current position

Job Title	Emeritus Professor of University		
Starting date	2018		
Institution	University of Seville		
Department / Centre	Medicine / School of Medicine		
Country	Spain	Phone Number	
Keywords	Antibiotics; Clinical medicine; Therapeutics		

A.3. Education

Degree/Master/PhD	University / Country	Year
Doctor en Medicina y Cirugía	Universidad de Sevilla / Spain	1974
Licenciado en Medicina y Cirugía	Universidad de Sevilla / Spain	1971

Part B. CV SUMMARY

Head of the research group "Infectious Diseases" at the Institute of Biomedicine of Seville, University Hospital Virgen del Rocío/CSIC/University of Seville and the Andalusian R+D+I Plan (PAIDI CTS-203) from 1986.

Research lines: i) Infections in immunosuppressed patients; ii) Microbial resistance; iii) Non-antimicrobial approaches in the treatment of multidrug-resistant Gram-negative bacilli; iv) New antibiotics and antivirals.

Author in 362 scientific manuscripts; Total citations without self-citations 7706; Index h: 51.

Fifteen patents of intellectual or industrial property, 2 licensed and 3 internationals.

Co-founder of spin-off biotechnology company Vaxdyn S.L. in 2011.

Director of 37 Doctoral Theses.

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Publications.

AC: corresponding author. (n° x / n° y); position / total authors. If applicable, indicate the number of citations

- Scientific paper.** S Salto-Alejandre; J Berastegui-Cabrera; P Camacho-Martínez; JM Cisneros; J Pachon; E Cordero; J Sánchez-Céspedes. 2021. SARS-CoV-2 viral load in nasopharyngeal swabs is not an independent predictor of unfavorable outcome Scientific Reports. 11-1, pp.12931.

- 2 **Scientific paper.** S Mazzotta; J Berastegui-Cabrera; M Vega-Holm; JM Vega-Pérez; J Pachon; F Iglesias-Guerra; J Sánchez- Céspedes. 2021. Design, synthesis and in vitro biological evaluation of a novel class of anti-adenovirus agents based on 3-amino-1,2-propanediol *BIOORGANIC CHEMISTRY*. 114, pp.105095.
- 3 **Scientific paper.** A Miró-Canturri; R Ayerbe-Algaba; R Del Toro; ME Mejías; J Pachon; Y Smani. 2021. Potential Tamoxifen Repurposing to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli *Pharmaceuticals (Basel)*. 14-6, pp.507.
- 4 **Scientific paper.** S Salto-Alejandre; S Jiménez-Jorge; N Sabé; J Pachon; J Sánchez-Céspedes; E Cordero. 2021. Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort study *Plos One*. 16, pp.e0250796.
- 5 **Scientific paper.** T Cebrero-Cangueiro; G Labrador-Herrera; A Pascual; et al;. 2021. Efficacy of Fosfomycin and Its Combination With Aminoglycosides in an Experimental Sepsis Model by Carbapenemase-Producing *Klebsiella pneumoniae* Clinical Strains *Front Med (Lausanne)*. 8, pp.615540.
- 6 **Scientific paper.** A Miró-Canturri; R Ayerbe-Algaba; A Vila-Domínguez; ME Jiménez-Mejías; J Pachon; Y Smani. 2021. Repurposing of the Tamoxifen Metabolites to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli *Antibiotics (Basel)*. 10, pp.336.
- 7 **Scientific paper.** J Berenguer; AM Borobia; P Ryan; et al;. 2021. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score *Thorax*. Epub ahead of print.
- 8 **Scientific paper.** B Gutiérrez-Gutiérrez; MD del Toro; AM Borobia; et al;. 2021. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study *Lancet Infect Dis*. Epub ahead of print.
- 9 **Scientific paper.** R Ayerbe-Algaba; N Bayo; E Verdu; et al;. 2021. AOA-2 Derivatives as Outer Membrane Protein A Inhibitors for Treatment of Gram-Negative Bacilli Infections *Front Microbiol*. 12, pp.634323.
- 10 **Scientific paper.** T Cebrero-Cangueiro; P Nordmann; M Carretero-Ledesma; J Pachon; ME Pachon-Ibañez. 2021. Efficacy of dual carbapenem treatment in a murine sepsis model of infection due to carbapenemase-producing *Acinetobacter baumannii* *J Antimicrob Chemother*. 76, pp.680-683.
- 11 **Scientific paper.** G Labrador-Herrera; AJ Perez-Pulido; R Álvarez-Marín; et al;. 2020. Virulence role of the outer membrane protein CarO in carbapenem-resistant *Acinetobacter baumannii* *Virulence*. 11, pp.1727-1737.
- 12 **Scientific paper.** J Berastegui-Cabrera; S Salto-Alejandre; M Valerio; J Pachon; JM Cisneros; E Cordero; J Sánchez-Céspedes. 2020. SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load *Journal of Infection*. 82, pp.e38-e41.
- 13 **Scientific paper.** S Salto-Alejandre S; C Roca-Oporto; J Pachon; JM Cisneros. 2020. A quick prediction tool for unfavourable outcome in COVID-19 inpatients: Development and internal validation *Journal of Infection*. 82, pp.e11-e15.
- 14 **Scientific paper.** J Rodríguez-Baño; J Pachon; J Carratalà; P Ryan; I Jarrin; M Yllescas; JR Arribas; J Berenguer. 2020. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) *Clin Microbiol Infect*. 27, pp.244-252.
- 15 **Scientific paper.** J Berenguer; P Ryan; J Rodríguez-Baño; I Jarrin; J Carratalà; J Pachon; M Yllescas; JR Arriba. 2020. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain *Clin Microbiol Infect*. 26, pp.1525-1536.
- 16 **Scientific paper.** Manuela Aguilar-Guisado; José Antonio Marrugal-Lorenzo; Judith Berastegui-Cabrera; Laura Merino; Jerónimo Pachon; Javier Sánchez-Céspedes. 2020. In vitro co-infection by cytomegalovirus improves the antiviral activity of ganciclovir against human adenovirus *Int J Antimicrob Agents*. 56, pp.106046.

- 17 Scientific paper.** María Luisa Gil Marqués; Gema Labrador Herrea; Andrea Miro Canturri; Jerónimo Pachón; Younes Smani; María Eugenia Pachón Ibáñez. 2020. Role of PstS on the pathogenesis of *Acinetobacter baumannii* under microaerobiosis and normoxia *Journal of Infectious Diseases*. 222, pp.1204-1212.
- 18 Scientific paper.** Andrea Miro Canturri; Rafael Ayerbe Algaba; Angel Rodriguez Villodres; Jeronimo Pachon; Younes Smani. 2020. Repositioning rafoxanide to treat Gram-negative bacilli infections *Journal of Antimicrobial Chemotherapy*. 75, pp.1895-1905.
- 19 Scientific paper.** J Xu; Judith Berastegui Cabrera; H Chen; Jeronimo Pachon; J Zhou; Javier Sanchez Cespedes. 2020. Structure-Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection *Journal of Medicinal Chemistry*. 63-6, pp.3142-3160.
- 20 Scientific paper.** J Sánchez Céspedes; JA Marrugal Lorenzo; C Martin Gandul; et al;. 2020. T-cells immune response controls the high incidence of adenovirus infection in adult allogenic hematopoietic transplantation recipients *Haematologica*. 106, pp.275-278.
- 21 Scientific paper.** A Rodríguez-Villodres; M Gil-Marqués; R Álvarez-Marín; et al;. 2020. Extended-spectrum resistance to β -lactams/ β -lactamase inhibitors (ESRI) evolved from low-level resistant *Escherichia coli* *Journal of Antimicrobial Chemotherapy*. 75-1, pp.77-85.
- 22 Scientific paper.** S Mazzotta; JA Marrugal-Lorenzo; M Vega-Holm; et al;. 2020. Optimization of piperazine-derived ureas privileged structures for effective antiadenovirus agents.*Eur J Med Chem*. 185, pp.111840.
- 23 Scientific paper.** EL Mangas; A Rubio; R Álvarez-Marín; G Labrador-Herrera; J Pachón; ME Pachón-Ibáñez; F Divina; AJ Pérez-Pulido. 2019. Pangenome of *Acinetobacter baumannii* uncovers two groups of genomes, one of them with genes involved in CRISPR/Cas defence systems associated with the absence of plasmids and exclusive genes for biofilm formation *Microbial Genomics*. 5-11, pp.e000309.
- 24 Scientific paper.** R Ayerbe-Algaba; ML Gil-Marques; A Miró-Canturri; R Parra-Millán; ME Pachón-Ibáñez; ME Jimenez-Mejias; J Pachón; Y Smani. 2019. The anthelmintic oxclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli *International Journal of Antimicrobial Agents*. 54-4, pp.507-512.
- 25 Scientific paper.** Espinal P; Pantel A; Rolo D; et al; Lavigne JP. 2019. Relationship Between Different Resistance Mechanisms and Virulence in *Acinetobacter baumannii*.*Microb Drug Resist*.25-5, pp.752-760.
- 26 Scientific paper.** Marrugal-Lorenzo JA; Serna-Gallego A; Berastegui-Cabrera J; Pachón J; Sánchez-Céspedes J. 2019. Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections.*Sci Rep*.9(1):17.
- 27 Scientific paper.** Parra-Millan R; Vila-Farres X; Ayerbe-Algaba R; et al; Smani Y. 2018. Synergistic activity of an OmpA inhibitor and colistin against colistin-resistant *Acinetobacter baumannii*: mechanistic analysis and in vivo efficacy.*J Antimicrob Chemother*. 1;73 (12), pp.3405-3412.
- 28 Scientific paper.** Gil-Marqués ML; Moreno-Martínez P; Costas C; Pachón J; Blázquez J; McConnell MJ. 2018. Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in *Acinetobacter baumannii*.*J Antimicrob Chemother*.1;73(11), pp.2960-2968.
- 29 Scientific paper.** Gil-Marques ML; Pachón-Ibáñez, ME; Pachón J; Smani Y. 2018. Effect of Hypoxia on the Pathogenesis of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* In Vitro and in Murine Experimental Models of Infection.*Infect Immun*.
- 30 Scientific paper.** Rodríguez-Villodres A; Ortiz de la Rosa JM; Álvarez-Marín R; Pachón J; Aznar J; Lepe JA; Smani Y. 2017. Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of *Escherichia coli* Sequence Type 131 *Antimicrob Agents Chemother*. 21;62(1).

C.3. R&D and innovation projects and contracts

- 1 Project.** Desarrollo y validación de nuevas tecnologías diagnósticas, detección de multirresistencia y de determinantes de virulencia, de manera precoz, en las bacteriemias por *Pseudomonas aeruginosa*. Instituto de Salud Carlos III. María Eugenia Pachón Ibáñez. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2021-31/12/2023. 98.010.

- 2 **Project.** Uso de agentes anti-cancerígenos como estrategia antimicrobiana para el tratamiento de las infecciones por bacilos gramnegativos. Institute of Health Carlos III. Manuel Enrique Jiménez Mejías. (Institute of Biomedicine of Seville). 01/01/2020-31/12/2022. 123.420.
- 3 **Project.** Evaluación, in vitro e in vivo, de la eficacia de pentamidina asociada a otros antimicrobianos en el tratamiento de enterobacterias productoras de carbapenemasas o resistentes a colistina. Institute of Health Carlos III. Rocío Álvarez Marín. (Institute of Biomedicine of Seville). 01/11/2019-31/12/2021. 178.172,5.
- 4 **Project.** Estudio de la carga viral de SARS-CoV-2 en vías respiratorias y sangre como factor asociado al pronóstico de la COVID-19 en adultos (COVID_CV).. Instituto de Salud Carlos III. Javier Sánchez Céspedes. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 30/04/2020-29/10/2021. 189.765.
- 5 **Project.** Multicenter study of coronavirus disease 2019 (COVID-2019) in Solid Organ Transplant Recipients (COVIDSOT, GESITRA/REIPI). Instituto de Salud Carlos III. María Elisa Cordero Matía. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 30/04/2020-29/10/2021. 182.201.
- 6 **Project.** (DTS17/00130) Nuevos compuestos innovadores derivados de piperazina para el tratamiento de infecciones causadas por virus oportunistas. Javier Sánchez Céspedes. (INSTITUTO DE BIOMEDICINA DE SEVILLA). 01/01/2017-31/12/2019. 33.550.
- 7 **Project.** (PI15/01358) Eficacia terapéutica de MV5 y sus derivados como terapia combinada con colistina en un modelo experimental murino de infección. Instituto de Salud Carlos III. Jerónimo Pachón Díaz. (FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA). 01/01/2016-31/12/2018. 212.052,5.
- 8 **Project.** PI12/02553, (PI12/02553) Estudio de los genes responsables de la patogenicidad de Acinetobacter baumannii en cepas clínicas productoras de infección y colonización. INSTITUTO DE SALUD CARLOS III - MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD. Jerónimo Pachón Díaz. (FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA). 01/01/2013-2015. 200.255. Co-ordinator.
- 9 **Project.** FP7-278232-1, (FP7-278232-1) Optimisation of treatment with off-patent antimicrobial agents of ventilator-associated pneumonia (VAP). 7th Framework Programme, FP7-HEALTH-2011-two-stage, HEALTH.2011.2.3.1-1. JOSÉ MIGUEL CISNEROS HERREROS. (FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA). 01/01/2012-2014. 5.987.998.
- 10 **Project.** IPT-2011-1270-900000, (IPT-2011-1270-900000) ACINETOVAX: Desarrollo preclínico de una nueva vacuna contra Acinetobacter baumannii multirresistente. CENTRO DE ACUSTICA APLICADA Y EVALUACION NO DESTRUCTIVA. MICHAEL MCCONNELL. (FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA). From 01/03/2012. 963,58.
- 11 **Contract.**

C.4. Activities of technology knowledge transfer and results exploitation

- 1 Jia Xhou; Jerónimo Pachón Díaz; Judith Berastegui Cabrera; María Eugenia Pachón Ibáñez; Javier Sánchez Céspedes; Jimin Xu. 46855. Salicylamide derivativs and related methods of making United States of America. 26/01/2020. University of Texas, USA. Servicio Andaluz de Salud, Andalucía, Spain. University of Seville, Spain.
- 2 Jerónimo Pachón Díaz; José Antonio Lepe Jiménez; Ángel Rodríguez Villodres; Younes Smani. P201930573. Kit y método de detección rápida de bacterias resistentes a las combinaciones de antibióticos betalactámicos con inhibidores de b-lactamasas, y de la resistencia de espectro extendido a los betalactámicos en aislados clínicos Spain. 21/06/2019. University of Seville and Servicio Andaluz de Salud.
- 3 Javier Sánchez Céspedes; María Eugenia Pachón Ibáñez; Jerónimo Pachón Díaz; Pablo Martínez Aguado; Tania Cebrero Canguero; José Manuel Vega Pérez; Fernando Iglesias Guerra; Margarita Vega Holm; José Ignacio Candela Lena; Sarah Mazzota. PCT/EP2017/054252. Piperazine derivatives as antiviral agents with increased therapeutic activity Spain. 23/08/2018. University of Seville and Servicio Andaluz de Salud.

- 4 Younes Smani; Jerónimo Pachón Díaz; Ernest Giral Lledó; Meritxell Teixidó Turá; Nueria Bayo Puxán; Jordi Vila Estapé; Xavier Vila Farres. PCT/EP2015/072166. Peptides against anti-outer membrane protein A (OmpA) to treat infections caused by Gram negative pathogens 25/09/2015. Servicio Andaluz de Salud, Universidad de Sevilla, Institut de Recerca Biomèdica, Universidad de Barcelona, Hospital Clinic Barcelona, IDIBAPS.
- 5 Younes Smani; Jerónimo Pachón Díaz. P201331715. Uso de la lisofosfatidilcolina para la prevención y/o tratamiento de infecciones causadas por *Acinetobacter baumannii* 26/05/2015. Servicio Andaluz de Salud, Universidad de Sevilla.

NOT VALID